Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study-Reference-Cited by-同舟云学术

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Published:2018-10 Issue:10 Volume:19 Page:1372-1384
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tabernero Josep,Hoff Paulo M,Shen Lin,Ohtsu Atsushi,Shah Manish A,Cheng Karen,Song Chunyan,Wu Haiyan,Eng-Wong Jennifer,Kim Katherine,Kang Yoon-Koo

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann Oncol,2008

2. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature;Lei;World J Surg Oncol,2017

3. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications;Ock;Gastric Cancer,2016

4. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

5. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Smyth;Ann Oncol,2016

Cited by 354 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study;Translational Oncology;2024-11

2. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

3. HER2-low gastric cancer: is the subgroup targetable?;ESMO Open;2024-09

4. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

5. The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer;Cancers;2024-08-26